Diagnosis
In assessing outcome it is important in the first place to make an accurate diagnosis. Too many trials have suffered from a heterogeneous patient population, thus obscuring real differences of treatment. One rheumatic disease in which great progress in therapy has been made is gout. For the acute attack indomethacin given in a dose of 100 mg four-hourly until symptoms begin to ameliorate, then in a rapidly reducing dose, produces complete relief of pain, increased range of movement, and decrease in the circumference of the affected joint. For interval treatment aimed at reducing the level of serum uric acid, uricosuric agents may be used. Sometimes they are ineffective or there may be crystalluria or renal stones, which makes this treatment inappropriate. In such cases allopurinol is effective in reducing the level of serum uric acid by xanthine oxidase inhibition. Crystalluria stops and no further stones are formed. These treatments have dramatically altered the outlook for patients with this disease. Before 1950 they suffered frequently from acute attacks, classically beginning with podagra. The acute attacks were controlled with colchicine, but chronic tophaceous gout often developed. Now with uricosuric drugs or allopurinol the uric acid can be kept to normal levels and colchicine 0.5 mg three times daily will prevent acute attacks whilst the uric pool is being mobilized.
Another disease in which the outcome has been dramatically altered is polymyalgia rheumatica. This disease, predominantly of elderly women, is diagnosed clinically. The criteria for diagnosis have been elucidated by Bird et al. (1979) and the sensitivity and relative value of these discriminatory features are shown in Table 1 . The symptoms are completely abolished by the administration of prednisolone, and the raised ESR rapidly falls to normal. Recently we have set up a study to establish the value of monitoring acute-phase reactants in predicting relapse in this condition, since it is necessary to know when patients can be weaned from steroids (Hickling et al. 1985) . Patients with polymyalgia rheumatica who had been on steroids for more than a year were admitted to the Regional Rheumatology Unit at the Royal Bath Hospital, Harrogate. Their prednisolone was reduced in steps of 1 mg every 48 hours until they were completely weaned from the drug or until there was a symptomatic relapse. Daily assessments were made clinically, and acute-phase reactants determined every two days. In 11 of 16 patients so studied, the steroids could be withdrawn. It was found, however, that no single acute-phase reactant predicted relapse. We have come to rely on the ESR and plasma 'Philip Ellman Memorial Lecture delivered to the Section of Medicine, Experimental Medicine & Therapeutics, Curves showing the quality of life in patients receiving second-line anti-rheumatoid drugs, and those not viscosity together. If they rise during the withdrawal of prednisolone, the programme is stopped. Although C-reactive protein is the most rapid to respond to the administration of steroids, it did not prove helpful in predicting relapse.
Definition
Although 'outcome' is frequently discussed in the therapeutic literature, it is seldom defined. A cynical definition of a successful outcome has been 'one in which the patient does not bother you again with that problem'! The dictionary is of little help in this respect, merely telling us that outcome is 'the issue', 'consequence', or 'result'. There are those who think of outcome only in terms of what ultimately transpires. As Figure 1 shows, this may be misleading. In rheumatoid arthritis, whatever the intervention measures, the ultimate condition of the patient may be similar. However, by the administration of antirheumatoid drugs disability may be reduced for periods, and other outcome measures such as laboratory variables improved. In that case the 'area under the curve' is significantly different from those patients who do not receive antirheumatoid therapy. This improvement in the quality of life is not to be despised. Therefore, in talking of outcome we do well to consider immediate improvement, intermediate amelioration, and ultimate prognosis.
Subjective symptoms
In a study of 250 consecutive patients at our Rheumatism Clinic, we found that pain was the most important symptom in two-thirds of 122 patients with rheumatoid arthritis, and in threequarters of 53 patients with osteoarthritis. Stiffness was the most important in 12% and 6%, and disability in 22% and 15% respectively. This is particularly relevant in considering the role of non-steroidal anti-inflammatory drugs (NSAIDs). In a trial comparing indomethacin with phenylbutazone, using for the first time in rheumatology a double-dummy technique, we calculated optimal practical weights for the variables measured (McGuire & Wright 1971) . It was found that 80% of the variation during the study was given by improvement in pain and reduction of aspirin need.
Because of the importance of pain, there have been attempts to quantitate this numerically, particularly using visual analogue scales (Huskisson 1974 , Dixon & Bird 1981 . The sources of error of this type of investigation are well known. The patients may not understand the instructions; if back pain is being assessed, they sometimes equate a vertical visual analogue scale with the spinal column and mark the line according to where the pain is rather than its severity. The level of depression will affect the rating given, as will the presence of the spouse. If the scale is not viewed from above, errors may be introduced. Variations ini the length of line may also be introduced in photocopying. In a study of the reproducibility of a vertical visual analogue scale in our Unit, it was found that the least variation was at the ends of the line, and that the greatest standard deviation was at the golden sector of the linethat point on a line which divides it into two segments such as the smaller is to the larger, what the larger is to the whole line; this is about 62% along the length (Dixon & Bird 1981) . More recently we have studied the value of visual analogue scales in recalling pain experiences (Hinchcliffe et al. 1985) . Thirty rheumatoid patients were studied using 10 cm vertical and horizontal scales. The patient was asked, 'How bad is the pain in your joints at the present time?', and this was marked by them on the scale. One hour later the question was put, 'How bad was the pain in your joints one hour ago?', and the line was marked accordingly. The procedure was repeated the following day at the same times. There was an excellent correlation between the values on the vertical and horizontal scales. There were, however, considerable differences after one hour, which were more marked on the second day. This calls into question the use of these scales when considering pain over a week. If patients cannot remember for an hour, it is unlikely that they will remember accurately for a week.
In the context of the assessment of the effect of NSAIDs, the work of Umbenhauer (1981) is interesting. He analysed a large number of trials and found that for patients with rheumatoid arthritis the only variables worth measuring were articular index (Ritchie et al. 1968 ), pain score, and global response. In patients with osteoarthritis the global response of the patient was the only measure of value. O'Brien (1968) compared trials of indomethacin in which only subjective measures were reported and those in which some objective assessments were included. Of 607 patients measured subjectively 56% improved, whereas of 218 who were assessed objectively only 34% improved.
In an attempt to measure pain objectively, we have considered its effect on sleep. It has been known from antiquity that pain disturbs sleep. In Job chapter 7, verses 3 and 4, the sufferer exclaims, 'So I am made to possess months of vanity and wearisome nights are appointed to me. When I lie down, I say, when shall I arise, and the night be gone? And I am full of tossings to and fro until the dawning of the day'. In a study of 200 outpatients we found that 67% of 100 rheumatoid patients and 70% of 100 osteoarthritic patients had sleep disturbance; 24% of the rheumatoids and 18% of the osteoarthritics required sleeping tablets. The main reason for the disturbance of sleep was pain in 94% of rheumatoids and 90% of osteoarthritics. Others experienced restlessness, cramp, dreams and needing to get up to pass urine. In order to quantify sleeping at night we have used electroencephalography (EEG) and motilhty. The latter was measured by placing a pressure transducer in the leg of the bed. The EEG changes in the phases of sleep are alpha activity seen posteriorly when the patient is awake with the eyes closed, low-voltage irregular components characteristic of drowsiness, sleep spindles seen in light sleep particularly at the front of the head, vertex sharp waves observed in light sleep, 988 Journal ofthe Royal Society ofMedicine Volume 78 December 1985 irregular high-voltage delta activity characteristic of deep sleep, and low voltage arrhythmic pattern during rapid-eye-movement sleep. We have been doing a crossover trial of medications to observe alterations in pattern of sleep in patients with osteoarthritis. Motility in sleep is variable, ranging from less than 10 turns in the night in the majority to over 50 turns in some patients. It is felt that such objectivity may well be of value, since Kirwan et al. (1983a, b ) have shown, using paper patients, that in the assessment of the activity of rheumatoid disease rheumatologists are not consistent within themselves or between themselves.
Objective clinical measures

Stiffness
Morning stiffness is a diagnostic criterion of rheumatoid arthritis (Ropes et al. 1959) . Its duration is a measure of the activity of the disease (Lansbury 1958) . Articular gelling is common in all forms of arthritis, with immobility stiffness after sitting for a period. The degree of this stiffness helps to measure the progress of the disease. Physical stiffness has been used to determine changes in structures such as polymer rubbers, and is likely to reflect changes in the articular structures. Nevertheless, morning stiffness is a fickle symptom. In 467 subjects between the ages of 55 and 64 in a population survey, 132 said they experienced stiffness in the morning when they were questioned at home. These subjects were brought to hospital, and 118 on re-questionning said that they were stiff in the mornings. However, only 74 gave a positive answer on both occasions.
Arthrographs for the knee and for the metacarpophalangeal (MCP) joint have been developed to measure stiffness objectively. Goddard et al. (1969) , in our Unit, employed a sinosoidal motion to investigate the knee, and measured the resistive torque, plotting it in relation to angular displacement. To overcome inertial effects, Thompson et al. (1978) produced an alternative knee arthograph in which the patient's knee was flexed horizontally with the patient lying on his side. More work has been done with the finger (Wright & Johns 1960 , Scott 1960 , Hicklin et al. 1968 , Barnett & Cobbold 1968 , Grahame & Jenkins 1972 , Unsworth et al. 1981 ). Recently we have devised an arthrograph for the MCP joint in which the finger is moved laterally (Howe et al. 1985) . Age and sex changes in the stiffness at the MCP joint had been noted previously. The results from this apparatus suggest, however, that if the finger circumference is taken into account, most of the variation in dissipative torques and elastic stiffness can be explained on this basis. Injection of local steroid into MCP joints with active synovitis produced a marked reduction of stiffness. Interestingly, when the results from the rheumatoid patients were placed on the graphs of normal subjects, it was found that they tended to lie in the lower percentiles, and after injection were well below the normal range in the majority of patients. This suggests that the stiffness experienced by patients is not so much a function of the physical stiffness of tissues around the joint, but the limitation in movement imposed on the joint.
Grip strength
Measurement of grip strength using a pneumatic dynamometer is most commonly employed in clinical trials of patients with rheumatoid arthritis. More recently we have developed a pinch/grip analyser. The patients grip two padded bars for a period of eight seconds, when a bell rings and they release their grip. The information which can be obtained from this apparatus is illustrated in Figure 2 : the maximum grip, the grip rate, fatigue rate, the amount of fatigue, release rate, and the power factor (being the area under the curve).
Range ofmovement
Range of active movement has been measured goniometrically, and in the case of the thoracolumbar spine by tape measure. Hydrogoniometers have also been devised for such measurements. This has been discussed in detail elsewhere (Wright 1982) . Electrogoniometers enable dynamic measurements to be made. We have telemeterized these goniometers, obviating the need for trailing wires. Passive movement is important in evaluating conditions such as the hypermobility syndrome. A hyperextensometer measures the -extensibility of the MCP joint when a pre-set torque is applied . Because of the development in our Bioengineering Group of an artificial ligament for the replacement of damaged knee ligaments, Mr J Dahlqvist has devised a knee analyser (Figure 3 ). This measures anteroposterior movement, tibial rotation, and varug-valgus movements. Figure 4 shows the distribution of results from patients with medial collateral ligament damage compared with normal subjects. The valgus laxity in normal subjects was 0.05 + 0.82 degrees compared with 0.72 + 1.94 in patients with medial lateral ligament damage, when comparing the two legs. Figure 5 shows the results for anterior cruciate ligament damage. The anterior laxity in a normal group of subjects was 0.38 + 0.74, whereas in patients with anterior cruciate ligament damage it was 1.45 + 1.03, comparing the two legs.
Laboratory variables
Because there is no animal model for the evaluation of second-line drugs on rheumatoid arthritis, we have devised a patient model system as a screening test for potential antirheumatoid (Figure 6 ). Over a six-month period patients are evaluated clinically in terms of pain, articular index, grip strength, size of proximal interphalangeal joint, summated change score, function, aspirin need, and duration of morning stiffness. At the same time a battery of blood tests are done, including haemoglobin, white count, ESR, platelets, viscosity, C-reactive protein, haptoglobin, fibrinogen, histidine, sulphydryl, urea and electrolytes, creatinine, liver function tests, alkaline phosphatase, gamma glutamyl transpeptidase, complement, immunoglobulins, and rheumatoid factor. X-rays of the hands and feet are taken at the beginning and end of this study period. We are able to look at the changes with time (Figures 7 and 8) , and observe significant changes with the established second-line agents such as penicillamine, gold T IMEI(WEEKS TIME(UEWKS) Figure 8 . Changes in the plasma viscosity over a 6 month period after 6 drugs. (-= significant improvement) and hydroxychloroquine. Correlation matrices enable us to see at a glance whether there are many significant correlations between the clinical and biochemical variables (Table 2) . A large number of significant associations indicates second-line activity, whereas there are few such correlations with NSAIDs.
This matrix has been refined to reduce the biochemical variables to plasma viscosity, C-reactive protein, sulphydryl, histidine, IgM and haemoglobin. This mini-matrix serves to differentiate compounds (Table 3) . Our confidence in the system has been increased by the fact that each new compound, which has been submitted to formal clinical trial, having shown promise in the patient model system, has demonstrable activity. An example of this is sulphasalazine (Neumann et al. 1983 ). The patient model system is not only useful for screeining potential second-line agents, but also gives an indication of the mechanism of action of the drugs. Thus, we have looked at trien, which is used as a copper chelator in Wilson's disease when the patient is sensitive to penicillamine. Although trien reduces the level of copper in Wilson's disease, as penicillamine does, it proved ineffective in rheumatoid arthritis, suggesting that however penicillamine works, its copper-chelating properties are unlikely to be responsible (Dixon et al. 1984) .
We have been looking at the biochemical tests of response to see if they can be further refined (Dixon, unpublished data) . The preliminary conclusions are that there is unlikely to be one optimum test reflecting response to drugs. A small group is probably the most useful, and a group of such tests are needed to identify drug actions for novel agents. The biochemical tests are more reproducible than clinical measures. Plasma viscosity, C-reactive protein, sulphydryl and histidine in combination distinguish second-line agents from NSAIDs. Plasma viscosity and C-reactive protein are rapid indicators, but histidine and sulphydryl may reflect more basic changes.
Therapeutic index
In assessing outcome in response to treatment, efficacy must be related to the toxicity of preparations. For this reason a side-effects questionnaire must be included in clinical trials, haematological and biochemical profiles undertaken and, where possible, a person at risk identified either by their sulphoxidation status or the possession of certain histocompatibility antigen types (Panayi et al. 1978) .
Radiological assessment
The nearest we can get to evaluating serially the actual changes in the joints is by radiology. A variety of outcome measures have been used; erosion counts in selected joints, counts ofjoints involved, visual analogue scale of joint damage, and microfocal radiography (Buckland Wright 1983) . In a study of clozic in rheumatoid arthritis we were able to show that the progress of erosions over a year in patients with early disease was significantly correlated with the height of the ESR (Rushton et al. 1983) . The X-ray progression was less in those patients who went into remission and whose ESR returned to normal limits.
Functional improvement
The assessment of long-term outcome in rheumatoid arthritis is beset by statistical difficulties. The disease is variable, the drugs lack efficacy with time, and adverse reactions necessitating withdrawal of drugs are frequent (Jaffe 1984) . The Stanford group (Fries et al. 1980) has made a determined effort to quantitate outcome in rheumatic diseases by looking at five dimensions: death, discomfort, disability, drug toxicity and dollar costs. In 500 patients with rheumatoid arthritis and 300 patients with osteoarthritis they have validated this questionnaire. A Disability Index has been devised which is capable of quick application for sequential studies. It involves the degree of difficulty on a scale from 0 to 3 for dressing, bathing, eating, walking, standing, reaching, gripping, and general activity. Table 2 This is likely to prove a useful tool when large numbers of patients need to be studied over a prolonged period. It would have delighted Phillip Ellman, in that it involves primarily clinical studies.
Summary
In the assessment of outcome in rheumatic diseases a number of factors must be taken into account.
(1) It is important to make an accurate diagnosis, so that the response to treatment is not confused by heterogeneity of the population.
(2) The meaning of outcome needs to be defined. The quality of life over a prolonged period is just as important as the ultimate outcome.
(3) Subjective symptoms are important to the patient. Pain is the most important, followed by disability and then stiffness. Despite attempts to produce numerical values for pain, particularly visual analogue scales, patients' accuracy in recalling pain experienced more than an hour previously is dubious. In an attempt to quantify this aspect we have measured disturbance of sleep by changes in the EEG and in the motility of the patient.
(4) Objective clinical measures are desirable for accuracy. Arthrographs of the knees and metacarpophalangeal joints have produced useful data for physical stiffness. It is doubtful, however, whether they truly reflect the subjective stiffness of which the patient complains.
That is more likely to be due to limitation of motion. Grip strength is commonly measured by a pneumatic dynomometer, but a pinch/hand grip analyser promises to give more extensive information. Active movement has been measured goniometrically. of the knee can be measured on the Leeds Knee Analyser and differentiates collateral ligament damage and anterior cruciate ligament damage.
(5) Laboratory variables are important in a patient model system in which potential antirheumatoid drugs can be screened and their mechanism of action investigated. Correlation matrices separate second-line agents from NSAIDs. Although mini-matrices have been produced, it would not appear that any single biochemical test will suffice to differentiate these two classes of drugs. (6) A therapeutic index, in which the efficacy is expressed as a ratio of the toxicity of the drug, is important in determining its value. (7) The nearest we can get to serial assessment of the pathological changes in the joint is by X-ray assessment. Changes radiologically correlate to some extent with the height of the ESR, and their progress with changes in the ESR. (8) Functional impairment is important to the patient in the long term, and the Disability Index devised by the Stanford group commends itself for extensive long-term studies.
